Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study
Georg M. Stettner, Oswald Hasselmann, Anne Tscherter, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Challenges and opportunities in spinal muscular atrophy therapeutics
Crystal Jing Jing Yeo, Eduardo F. Tizzano, Basil T. Darras
The Lancet Neurology (2024) Vol. 23, Iss. 2, pp. 205-218
Closed Access | Times Cited: 21
Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy
Edmar Zanoteli, Alexandra Prufer de Queiroz Campos Araújo, Michele Michelin Becker, et al.
Arquivos de Neuro-Psiquiatria (2024) Vol. 82, Iss. 01, pp. 001-018
Open Access | Times Cited: 10
Nusinersen therapy changed the natural course of spinal muscular atrophy type 1: What about spine and hip?
Niyazi Erdem Yaşar, Güzelali Özdemir, Elif Uzun Ata, et al.
Journal of Children s Orthopaedics (2024) Vol. 18, Iss. 3, pp. 322-330
Open Access | Times Cited: 7
Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study
Claudia Weiß, Lena‐Luise Becker, Johannes Friese, et al.
The Lancet Regional Health - Europe (2024) Vol. 47, pp. 101092-101092
Open Access | Times Cited: 7
Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom
Vasantha Gowda, Mark Atherton, Archana Murugan, et al.
The Lancet Regional Health - Europe (2023) Vol. 37, pp. 100817-100817
Open Access | Times Cited: 16
A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Besarte Vrellaku, I. S. M. Hassan, Rebecca Howitt, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3220-3259
Open Access | Times Cited: 6
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians
Sithara Ramdas, Maryam Oskoui, Laurent Servais
Drugs (2024) Vol. 84, Iss. 7, pp. 747-762
Closed Access | Times Cited: 5
Early Development of Spinal Deformities in Children Severely Affected with Spinal Muscular Atrophy after Gene Therapy with Onasemnogene Abeparvovec—Preliminary Results
Venla Soini, Gudrun Schreiber, Bernd Wilken, et al.
Children (2023) Vol. 10, Iss. 6, pp. 998-998
Open Access | Times Cited: 13
Safety Concerns with Nusinersen, Risdiplam, and Onasemnogene Abeparvovec in Spinal Muscular Atrophy: A Real-World Pharmacovigilance Study
Wei Zhuang, Mei Lu, Ye Wu, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 12, pp. 949-962
Closed Access | Times Cited: 11
Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study
Ilaria Bitetti, Maria Rosaria Manna, Roberto Stella, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 4
Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy
Katy Cooper, Gamze Nalbant, Anthea Sutton, et al.
International Journal of Neonatal Screening (2024) Vol. 10, Iss. 3, pp. 56-56
Open Access | Times Cited: 4
Real-world multidisciplinary outcomes of onasemnogene abeparvovec monotherapy in patients with spinal muscular atrophy type 1: experience of the French cohort in the first three years of treatment
Isabelle Desguerre, Rémi Barrois, Frédérique Audic, et al.
Orphanet Journal of Rare Diseases (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 4
Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
Wenwen Zhang, Yizhen Yin, Dan Yang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
A state-of-the-art review of registries in spinal muscular atrophy: A valuable resource for clinical research
Lakshmi Balaji, Michelle A. Farrar, Eppie M. Yiu, et al.
Journal of Neuromuscular Diseases (2025)
Closed Access
Scoliosis in spinal muscular atrophy in the era of disease-modifying therapy: a scoping review
Martina Gnazzo, Giulia Pisanò, Benedetta Piccolo, et al.
Neurological Sciences (2025)
Open Access
Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy
Peerada Pongsakornkullachart, Pimchanok Kulsirichawaroj, Ratcharin Kongkasuwan, et al.
Gene Therapy (2025)
Open Access
Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio
Megan A. Waldrop, Shannon Chagat, Michael A. Storey, et al.
Neuromuscular Disorders (2023) Vol. 34, pp. 41-48
Closed Access | Times Cited: 8
Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression
Hoi Ning Hayley Ip, Michael Kwan Leung Yu, Wilfred Hing Sang Wong, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 349-359
Open Access | Times Cited: 2
Acceptability, validity and responsiveness of inertial measurement units for assessing motor recovery after gene therapy in infants with early onset spinal muscular atrophy: a prospective cohort study
Rémi Barrois, Brian Tervil, Marine Cacioppo, et al.
Journal of NeuroEngineering and Rehabilitation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 2
Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review
Nerea García-González, Jaime Gonçalves-Sánchez, Ricardo Gómez‐Nieto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12485-12485
Open Access | Times Cited: 2
Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study
Rémi Barrois, Lucie Griffon, Christine Barnérias, et al.
Sleep Medicine (2024) Vol. 119, pp. 335-341
Closed Access | Times Cited: 1
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Brenda Alves, Alexandra Prufer de Queiroz Campos Araújo, Flávia Nardes, et al.
Arquivos de Neuro-Psiquiatria (2024) Vol. 82, Iss. 11, pp. 001-008
Open Access | Times Cited: 1
Defining Meaningful Outcomes for Patients with Spinal Muscular Atrophy in the Era of Gene Therapy
Jana Haberlová, Francesco Muntoni, Eugenio Mercuri, et al.
EMJ Neurology (2023), pp. 72-81
Open Access | Times Cited: 1
Impact of Disease-modifying Therapies on Respiratory Function in People with Neuromuscular Disorders
Lena Xiao, Reshma Amin
Sleep Medicine Clinics (2024)
Closed Access
Onasemnogene abeparvovec gene therapy for spinal muscular atrophy: A cohort study from the United Arab Emirates
Vivek Mundada, Omendra Narayan, Siddharth Arora, et al.
Muscle & Nerve (2024)
Closed Access
Page 1 - Next Page

Scroll to top